CXCR2

Across TCGA pan-cancer cohorts, CXCR2 Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated CXCR2 data layer compared with 28 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher CXCR2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CXCR2 expression acts as an unfavorable survival marker.

OV, BLCA, and THCA are the cancer types where CXCR2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.007	0.844	<.001	48	view →
BLCA	OS	Median	All	0.153	0.720	<.001	45	view →
THCA	OS	Median	All	0.098	0.941	<.001	42	view →
TGCT	DFS	Median	II,III,IV	0.015	0.919	<.001	18	view →
SARC	OS	Median	All	0.085	0.827	<.001	12	view →
HNSC	OS	Median	All	0.069	0.768	<.001	12	view →
PRAD	DFS	Median	All	0.617	0.886	.035	6	view →
SKCM	OS	Median	IV	0.415	0.861	.014	6	view →
LGG	DFS	Median	All	0.559	0.826	.001	4	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

CXCR2–OV (OS)

Open the OV breakdown →